Erasca, Inc. (ERAS) Stock Ticker
ERAS right now
Market factors today
Unlock the full ERAS picture
About Erasca, Inc.
Erasca, Inc. is a biopharmaceutical company in the clinical development stage, primarily focused on identifying, advancing, and commercializing therapeutic solutions for malignancies propelled by the RAS/MAPK pathway. The firm's pipeline features several key experimental drugs: ERAS-007, an orally administered ERK1/2 inhibitor designed to address non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; and ERAS-601, an oral SHP2 inhibitor targeting patients with advanced or metastatic solid tumors. Additionally, Erasca is progressing ERAS-801, an EGFR inhibitor capable of penetrating the central nervous system, intended for recurrent glioblastoma multiforme. The company was founded in 2018 and maintains its headquarters in San Diego, California.
ERAS stock facts
| Ticker symbol | ERAS |
| Exchange | NASDAQ Global Select |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market cap | $4.9B |
| CEO | Jonathan E. Lim |
| Employees | 103 |
| Headquarters | San Diego, CA, US |
| IPO date | 2021-07-16 |
| Website | www.erasca.com |
What you can see for ERAS on Tickr
Live ERAS price chart with overlays, the options chain, implied move, IV rank, options flow and Strategy Lab, financial statements and consensus estimates, analyst ratings, catalysts, news with AI scoring, and an AI chat that has read the ERAS report.
Rankings
FAQ
What is the ticker symbol for Erasca, Inc.?
The ticker symbol for Erasca, Inc. is ERAS, listed on the NASDAQ Global Select.
What is ERAS?
Erasca, Inc. is a biopharmaceutical company in the clinical development stage, primarily focused on identifying, advancing, and commercializing therapeutic solutions for malignancies propelled by the RAS/MAPK pathway. The firm's pipeline features several key experimental drugs: ERAS-007, an orally administered ERK1/2 inhibitor designed to address non-small cell lung cancer, colorectal cancer,…